ATXI — Avenue Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.07m
- -$2.89m
- 18
- 59
- 63
- 44
Annual income statement for Avenue Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 5.21 | 3.74 | 8.04 | 14.5 | 11.3 |
| Operating Profit | -5.21 | -3.74 | -8.04 | -14.5 | -11.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.15 | -3.73 | -3.6 | -10.5 | -11.7 |
| Net Income After Taxes | -5.15 | -3.73 | -3.6 | -10.5 | -11.7 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.15 | -3.73 | -3.55 | -10.4 | -11.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.15 | -3.73 | -3.55 | -10.4 | -11.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -351 | -247 | -122 | -73.5 | -9 |